Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigette Ma

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignanciesVincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Journal of the National Cancer Institute|October 20, 2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaWinnie Yeo, Tony S Mok, Benny Zee, et al.
JCO Global Oncology|April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional StudyBhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
JCO Global Oncology|January 23, 2025
Precision Oncology: A Global Perspective on Implementation and Policy DevelopmentDenis Horgan, Marcel Tanner, Charu Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu-Pei Chen, Nofisat Ismaila, Melvin L K Chua, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignanciesVincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Journal of the National Cancer Institute|October 20, 2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaWinnie Yeo, Tony S Mok, Benny Zee, et al.
JCO Global Oncology|April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional StudyBhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
JCO Global Oncology|January 23, 2025
Precision Oncology: A Global Perspective on Implementation and Policy DevelopmentDenis Horgan, Marcel Tanner, Charu Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu-Pei Chen, Nofisat Ismaila, Melvin L K Chua, et al.
Clinical Colorectal Cancer|October 27, 2016
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyAnn-Lii Cheng, Gerardo Cornelio, Lin Shen, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Pageof 5